Masimo Co. (NASDAQ:MASI) Receives $145.33 Average PT from Brokerages

Masimo Co. (NASDAQ:MASI) has earned an average rating of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $145.33.

A number of equities research analysts have recently weighed in on MASI shares. BTIG Research lifted their price target on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Piper Sandler reaffirmed an “overweight” rating on shares of Masimo in a report on Friday, October 18th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Friday, September 20th.

Masimo Stock Down 0.9 %

NASDAQ:MASI opened at $140.74 on Friday. The company has a market capitalization of $7.48 billion, a price-to-earnings ratio of 95.74 and a beta of 0.99. Masimo has a one year low of $75.36 and a one year high of $153.93. The stock has a 50-day simple moving average of $127.05 and a 200 day simple moving average of $125.29. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. The business had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period last year, the firm earned $0.62 earnings per share. Sell-side analysts predict that Masimo will post 3.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Masimo

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MASI. Riverview Trust Co bought a new stake in Masimo during the first quarter worth approximately $25,000. NBC Securities Inc. raised its holdings in Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 73 shares in the last quarter. GAMMA Investing LLC raised its holdings in Masimo by 75.0% during the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 111 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 200 shares during the last quarter. Finally, HHM Wealth Advisors LLC grew its position in Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after buying an additional 125 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.